ReviewFrontiers in aging neuroscience2026
ZCCHC17: a target for synaptic dysfunction and neuronal excitability in Alzheimer's disease.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epileptic activity and neuronal excitability have been reported in the setting of Alzheimer's disease (AD), and may be linked to disease progression and severity. A shift in the excitation/inhibition balance to favor a more excitatory-dominant outcome appears to underlie the overall hyperactivity, with key mechanisms known to regulate excitatory and inhibitory neurotransmission in the brain being primarily affected. Synaptic dysfunction is a critical event in AD pathogenesis. Recent research suggests that the zinc finger protein, ZCCHC17 (Zinc Finger CCHC-Type Containing 17), serves as a potential master regulator of synaptic dysfunction in AD, with expression significantly reduced in the AD brain prior to gliosis and neuronal loss. Reduced levels of ZCCHC17 have been shown to lead to abnormal RNA processing and neuronal hyperexcitability. This review examines the specific role of ZCCHC17 in the AD brain, and discusses how ZCCHC17 may regulate mechanisms that underlie neuronal hyperexcitability. New insight into synaptic regulators of disease may contribute to improvements in early-stage diagnostics and interventions, and may better guide therapeutic approaches aimed at rescuing synaptic dysfunction in the prodromal stages of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.